IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v7y2016i1d10.1038_ncomms11579.html
   My bibliography  Save this article

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Author

Listed:
  • Jill M. Spoerke

    (Genentech, Inc)

  • Steven Gendreau

    (Genentech, Inc)

  • Kimberly Walter

    (Genentech, Inc)

  • Jiaheng Qiu

    (Genentech, Inc)

  • Timothy R. Wilson

    (Genentech, Inc)

  • Heidi Savage

    (Genentech, Inc)

  • Junko Aimi

    (Genentech, Inc)

  • Mika K. Derynck

    (Genentech, Inc)

  • Meng Chen

    (Genentech, Inc
    Present address: Roche China Holding, Shanghai 201203 China)

  • Iris T. Chan

    (Genentech, Inc)

  • Lukas C. Amler

    (Genentech, Inc)

  • Garret M. Hampton

    (Genentech, Inc)

  • Stephen Johnston

    (Royal Marsden NHS Foundation Trust)

  • Ian Krop

    (Dana-Farber Cancer Institute)

  • Peter Schmid

    (Barts Cancer Institute, Queen Mary University London)

  • Mark R. Lackner

    (Genentech, Inc)

Abstract

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in ESR1 and PIK3CA from ctDNA were assayed in clinical trial samples from ER+ metastatic breast cancer patients randomized either to the SERD fulvestrant or fulvestrant plus a pan-PI3K inhibitor. ESR1 mutations are present in 37% of baseline samples and are enriched in patients with luminal A and PIK3CA-mutated tumours. ESR1 mutations are often polyclonal and longitudinal analysis shows distinct clones exhibiting divergent behaviour over time. ESR1 mutation allele frequency does not show a consistent pattern of increases during fulvestrant treatment, and progression-free survival is not different in patients with ESR1 mutations compared with wild-type patients. ESR1 mutations are not associated with clinical resistance to fulvestrant in this study.

Suggested Citation

  • Jill M. Spoerke & Steven Gendreau & Kimberly Walter & Jiaheng Qiu & Timothy R. Wilson & Heidi Savage & Junko Aimi & Mika K. Derynck & Meng Chen & Iris T. Chan & Lukas C. Amler & Garret M. Hampton & St, 2016. "Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant," Nature Communications, Nature, vol. 7(1), pages 1-10, September.
    • Handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11579
    DOI: 10.1038/ncomms11579
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms11579
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms11579?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11579. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.